Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer

Ribociclib is an orally active, highly selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6. It is the second CDK 4/6 inhibitor approved for hormone receptor–positive breast cancer. The addition of ribociclib to an aromatase inhibitor has resulted in marked improvements in progression-free survival for patients with metastatic breast cancer. Clin Cancer Res; 24(13); 2981–3. ©2018 AACR.

See related article by Shah et al., p. 2999

https://ift.tt/2tQy46G